don’t know if it helps, but here is the answer i received from todd on 11/04
i would say they are gagged for unknown reason.
Hello xxx
I hope you are well.
My hope & expectations are we will be able to discuss corporate actions shortly. But is shortly tomorrow – next week – 3 weeks - more??? That I don’t know, & even if I did I couldn’t tell you.
What I do know is since SARS-CoV-2 came into our lives last February/March 2020, this company has had several significant issues to deal with.
I can tell you President & CEO Joe Moscato & our Management Team want nothing more than to address the shareholders, & a press release will be put out as soon as it is possible to do so.
Have events gone as planned? No… That said, we are not stopping & we are working to get things done, & announced as soon as possible.
I also add;
The Corporate Structure, Valuations & Listing details of NuGenerex Immuno-Oncology (NGIO) are expected soon.
All corporate filings for NuGenerex Immuno-Oncology Inc. (NGIO) are updated & filed as they happen. https://www.sec.gov/cgi-bin/browse-edgar?CIK=1804585
NUGX - are not the (NuGenerex Immuno-Oncology (NGIO)) shares that will be listed shortly by our company.
Those are the dividend shares that someone outside the company has listed to trade.
I politely reiterate, the activities surrounding the trading of NUGX is not from our company & I am not able to advise you on this trading.
Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution who facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.
For the sake of history since Jan 2017 when President & CEO Joe Moscato & his new team took over Generex Biotechnology Corp. & brought back from more or less being a dead corporation, there have been 5 corporate stock actions.
An original 1000 to 1 rollback of GNBT stock (Mach 2017)
1 share of (GNBT) stock got you 20 additional shares of (GNBT) stock Dec 3rd, 2018
5 shares of (GNBT) stock got you 2 additional shares of (GNBT) stock Feb 25th, 2020.
Also 2 sets of shares dividends of NuGenerex Immuno-Oncology / Formally Antigen Express - (not yet a publicly trading company).
Shares that were settled in accounts at the aforementioned dates are entitled to shares of: NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology shares.
4 (GNBT) shares got you 1 dividend share of (NGIO) Feb 26th, 2019 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.
5 (GNBT) shares got you 2 dividend shares of (NGIO) Feb 25th, 2020 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.
No shares that are tradeable public shares of (NGIO) NuGenerex Immuno-Oncology have been sent out.
The corporate structure is not finalized, the trading platform is not finalized.
Yes, NuGenerex Immuno-Oncology (Formally named Antigen Express) is considered a public company today but, no publicly listed shares have been issued from the company.
All shareholders of record will receive their dividends.
We work to get Generex Biotechnology Corp. back to the Nasdaq. Then firms, institutions, and the larger investor base that don’t buy OTC stocks will become interested in what we are doing.
That’s why we go to such lengths to file S-1’s so we can raise institutional money leading us to become Nasdaq compliant.
Why? How? They will buy stock & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
That’s what is being built, this is what Joe Moscato & our team is putting together.
Our President & Chief Executive Officer Joseph Moscato will continue to update shareholder as to pending acquisitions and previously discussed corporate actions.
We will continue to communicate with shareholders our company’s operational progress, strategic plans, and M&A activities as soon as they take place.
Information of the two NGIO share dividends to (GNBT) shareholders.
Shares that were settled in (OTCQB:GNBT) accounts at the aforementioned dates are entitled to shares of NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology.
4 to 1 dividend from Feb 26th, 2019
5 to 2 dividends from Feb 25th, 2020
NuGenerex Immuno-Oncology (Formally named Antigen Express) (NGIO) shares do not trade yet.
Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution that facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.
Keep in mind, the NGIO stock does not trade yet.
Transfer Agent (NEW)
https://www.stctransfer.com/
Securities Transfer Corporation
Plano, Texas
2901 Dallas Pkwy Suite 380,
Plano, TX 75093,
United States
1 469 633 0101
If you would like to discuss anything further please don’t hesitate to call me.
1 800 391 6755 x 222
Regards,
Todd
Todd Falls
Generex Biotechnology Corporation
Communication Director & Investor Relations Officer
USA Headquarters:
Generex Biotechnology, Inc.
10102 USA Today Way
Miramar, FL 33025
Direct Office:1-800-391-6755 - 222
phone: 416.364.2551 ext. 222
e-mail: tfalls@nugenerex.com
www.generex.com
Toronto Location:
4145 North Service Road, Suite 200
Burlington, Ontario
Canada L7L 6A3
Generex Biotechnology Subsidiaries:
AntigenExpress, Inc.
www.antigenexpress.com
Hema Diagnostics, Inc.
www.hemadiagnosticsystems.com
This electronic mail (e-mail) is intended solely for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable federal and international laws. If the reader of this communication is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this e-mail is strictly prohibited. If you have received this communication in error, please do not print, copy, re-transmit, disseminate, or otherwise use any of the information contained herein, and notify the sender immediately by replying to the e-mail address above. While messages are confidential, authorized management, legal and compliance personnel may review electronic messages. Electronic messages are also retained and would be provided upon request to an authorized regulatory body.
i would say they are gagged for unknown reason.
Hello xxx
I hope you are well.
My hope & expectations are we will be able to discuss corporate actions shortly. But is shortly tomorrow – next week – 3 weeks - more??? That I don’t know, & even if I did I couldn’t tell you.
What I do know is since SARS-CoV-2 came into our lives last February/March 2020, this company has had several significant issues to deal with.
I can tell you President & CEO Joe Moscato & our Management Team want nothing more than to address the shareholders, & a press release will be put out as soon as it is possible to do so.
Have events gone as planned? No… That said, we are not stopping & we are working to get things done, & announced as soon as possible.
I also add;
The Corporate Structure, Valuations & Listing details of NuGenerex Immuno-Oncology (NGIO) are expected soon.
All corporate filings for NuGenerex Immuno-Oncology Inc. (NGIO) are updated & filed as they happen. https://www.sec.gov/cgi-bin/browse-edgar?CIK=1804585
NUGX - are not the (NuGenerex Immuno-Oncology (NGIO)) shares that will be listed shortly by our company.
Those are the dividend shares that someone outside the company has listed to trade.
I politely reiterate, the activities surrounding the trading of NUGX is not from our company & I am not able to advise you on this trading.
Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution who facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.
For the sake of history since Jan 2017 when President & CEO Joe Moscato & his new team took over Generex Biotechnology Corp. & brought back from more or less being a dead corporation, there have been 5 corporate stock actions.
An original 1000 to 1 rollback of GNBT stock (Mach 2017)
1 share of (GNBT) stock got you 20 additional shares of (GNBT) stock Dec 3rd, 2018
5 shares of (GNBT) stock got you 2 additional shares of (GNBT) stock Feb 25th, 2020.
Also 2 sets of shares dividends of NuGenerex Immuno-Oncology / Formally Antigen Express - (not yet a publicly trading company).
Shares that were settled in accounts at the aforementioned dates are entitled to shares of: NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology shares.
4 (GNBT) shares got you 1 dividend share of (NGIO) Feb 26th, 2019 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.
5 (GNBT) shares got you 2 dividend shares of (NGIO) Feb 25th, 2020 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.
No shares that are tradeable public shares of (NGIO) NuGenerex Immuno-Oncology have been sent out.
The corporate structure is not finalized, the trading platform is not finalized.
Yes, NuGenerex Immuno-Oncology (Formally named Antigen Express) is considered a public company today but, no publicly listed shares have been issued from the company.
All shareholders of record will receive their dividends.
We work to get Generex Biotechnology Corp. back to the Nasdaq. Then firms, institutions, and the larger investor base that don’t buy OTC stocks will become interested in what we are doing.
That’s why we go to such lengths to file S-1’s so we can raise institutional money leading us to become Nasdaq compliant.
Why? How? They will buy stock & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.
That’s what is being built, this is what Joe Moscato & our team is putting together.
Our President & Chief Executive Officer Joseph Moscato will continue to update shareholder as to pending acquisitions and previously discussed corporate actions.
We will continue to communicate with shareholders our company’s operational progress, strategic plans, and M&A activities as soon as they take place.
Information of the two NGIO share dividends to (GNBT) shareholders.
Shares that were settled in (OTCQB:GNBT) accounts at the aforementioned dates are entitled to shares of NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology.
4 to 1 dividend from Feb 26th, 2019
5 to 2 dividends from Feb 25th, 2020
NuGenerex Immuno-Oncology (Formally named Antigen Express) (NGIO) shares do not trade yet.
Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution that facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.
Keep in mind, the NGIO stock does not trade yet.
Transfer Agent (NEW)
https://www.stctransfer.com/
Securities Transfer Corporation
Plano, Texas
2901 Dallas Pkwy Suite 380,
Plano, TX 75093,
United States
1 469 633 0101
If you would like to discuss anything further please don’t hesitate to call me.
1 800 391 6755 x 222
Regards,
Todd
Todd Falls
Generex Biotechnology Corporation
Communication Director & Investor Relations Officer
USA Headquarters:
Generex Biotechnology, Inc.
10102 USA Today Way
Miramar, FL 33025
Direct Office:1-800-391-6755 - 222
phone: 416.364.2551 ext. 222
e-mail: tfalls@nugenerex.com
www.generex.com
Toronto Location:
4145 North Service Road, Suite 200
Burlington, Ontario
Canada L7L 6A3
Generex Biotechnology Subsidiaries:
AntigenExpress, Inc.
www.antigenexpress.com
Hema Diagnostics, Inc.
www.hemadiagnosticsystems.com
This electronic mail (e-mail) is intended solely for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable federal and international laws. If the reader of this communication is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this e-mail is strictly prohibited. If you have received this communication in error, please do not print, copy, re-transmit, disseminate, or otherwise use any of the information contained herein, and notify the sender immediately by replying to the e-mail address above. While messages are confidential, authorized management, legal and compliance personnel may review electronic messages. Electronic messages are also retained and would be provided upon request to an authorized regulatory body.
5
